18-06-2018, 05:59 PM
China focused UK-based maker of affordable DNA sequencing kits eyes Hong Kong listing
Oxford Nanopore Technologies, spun-out from Oxford University, is aiming to take on US-based rival Illumina in the US$3 billion a year market by focusing on China, which accounts for 80 per cent of the world’s projects sequencing new genomes of animals and plants
Eric Ng
PUBLISHED : Monday, 18 June, 2018, 3:01pm
UPDATED : Monday, 18 June, 2018, 3:01pm
Oxford Nanopore Technologies, an affordable DNA sequencing devices supplier seeking to break the stranglehold of US rival Illumina in China, is considering a dual London-Hong Kong listing in the next 18 months, according to its chief executive.
The Oxford-based company, spun-out from Oxford University in 2005, is seeking to grab a slice of theUS$3 billion a year global market, in which Illumina has a 90 per share market share, by offering “starter pack” sequencers at US$1,000 to a much more sophisticated device valued at US$160,000, said Gordon Sanghera.
Prices of Illumina’s machines range from US$20,000 to US$10 million.
“Our goal it to give every single biologist the ability to analyse DNA, to check what they are doing in real time at their desks,” said Sanghera, who earlier played a key role in bringing to diabetics a finger-stick blood glucose testing device developed by Medisense, another Oxford spin-out acquired by US health care major Abbott.
More details in http://www.scmp.com/business/companies/a...-kits-eyes
Oxford Nanopore Technologies, spun-out from Oxford University, is aiming to take on US-based rival Illumina in the US$3 billion a year market by focusing on China, which accounts for 80 per cent of the world’s projects sequencing new genomes of animals and plants
Eric Ng
PUBLISHED : Monday, 18 June, 2018, 3:01pm
UPDATED : Monday, 18 June, 2018, 3:01pm
Oxford Nanopore Technologies, an affordable DNA sequencing devices supplier seeking to break the stranglehold of US rival Illumina in China, is considering a dual London-Hong Kong listing in the next 18 months, according to its chief executive.
The Oxford-based company, spun-out from Oxford University in 2005, is seeking to grab a slice of theUS$3 billion a year global market, in which Illumina has a 90 per share market share, by offering “starter pack” sequencers at US$1,000 to a much more sophisticated device valued at US$160,000, said Gordon Sanghera.
Prices of Illumina’s machines range from US$20,000 to US$10 million.
“Our goal it to give every single biologist the ability to analyse DNA, to check what they are doing in real time at their desks,” said Sanghera, who earlier played a key role in bringing to diabetics a finger-stick blood glucose testing device developed by Medisense, another Oxford spin-out acquired by US health care major Abbott.
More details in http://www.scmp.com/business/companies/a...-kits-eyes